Celina D'Cruz
机构: Principal Scientist, AstraZeneca
每年引用次数
引用次数
引用: 3,192
H-指数: 19
I10-指数 : 23
出版物: 63
Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).
Fabrice Andre , Erika P Hamilton , Sherene Loi , Peter Schmid
Journal of Clinical Oncology 39 ( 15_suppl) TPS1096 -TPS1096
10
2021
Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2–advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial.
Hope S Rugo , Mafalda Oliveira , Sacha Jon Howell , Florence Dalenc
Journal of Clinical Oncology 41 ( 16_suppl) 1067 -1067
2023
Molecular Assays for Chromosomal Translocations in the Diagnosis of Pediatric Soft Tissue Sarcomas
Frederic G Barr , Jane Chatten , Celina M D'Cruz , Albert E Wilson
JAMA: The Journal of the American Medical Association 273 ( 7) 553 -557
196
1995
Developmental stage determines the effects of MYC in the mammary epithelium.
Collin M Blakely , Louis Sintasath , Celina M D'Cruz , Kristina T Hahn
Development 132 ( 5) 1147 -1160
48
2005
Parity-Induced Protection Against Breast Cancer
Celina M D'Cruz , PENNSYLVANIA UNIV PHILADELPHIA
1999.
1999
c-Myc Transforms Human Mammary
Michael D Cole , Victoria H Cowling , Celina M D'Cruz , Lewis A Chodosh
A pharmacokinetic-pharmacodynamic model for the MET-TKI, savolitinib, to explore target inhibition requirements for anti-tumour activity
Rhys Jones , Mike Grondine , Alexandra Borodovsky , Maryann San Martin
Authorea Preprints
2020
Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
Hans-Christian Kolberg , Fabrice Andre , Erika Hamilton , Sherene Loi
ONCOLOGY RESEARCH AND TREATMENT 45 ( SUPPL 3) 32 -32
1
2022
Pregnancy-induced protection against mammary tumorigenesis (vol 66, pg 6421, 2006)
CM Blakely , AJ Stoddard , GK Belka , KD Dugan
CANCER RESEARCH 67 ( 2) 844 -846
2
2007
Use of conditional reprogramming to develop and characterize cell cultures from patient-derived xenograft (PDX) models of human lung and ovarian cancer
Alexandra Borodovsky , Travis J McQuiston , Brian Dougherty , Ambar Ahmed
Cancer Research 76 ( 14_Supplement) 641 -641
1
2016
Abstract OT-03-04: Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
Komal Jhaveri , Fabrice Andre , Celina D'Cruz , Erika Hamilton
Cancer Research 81
6
2021
Functional analysis of mammary development using oligonucleotide microarrays
Stephen Master , Jennifer Hartman , Alexander Stoddard , Elizabeth Keiper
Nature Genetics 27 ( 4) 47 -47
2001
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Celina D'Cruz , Lillian Castriotta , Stephen R. Wedge , Lara Ward
Molecular Cancer Therapeutics 14 ( 1) 48 -58
41
2015
Singular value decomposition-based regression identifies activation of endogenous signaling pathways in vivo
Zhandong Liu , Min Wang , James V Alvarez , Megan E Bonney
Genome Biology 9 ( 12) 1 -11
13
2008
Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)
Hazel Weir , Mandy Lawson , Rowena Callis , Michael Hulse
Cancer Research 75
2
2015
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Hazel M. Weir , Robert H. Bradbury , Mandy Lawson , Alfred A. Rabow
Cancer Research 76 ( 11) 3307 -3318
116
2016
Abstract A146: Preclinical models relevant to the treatment of post-menopausal breast cancer.
Ermira Pazolli , Anne Marie Mazzola , Jon Curwen , Hazel Weir
Molecular Cancer Therapeutics 12
2013
A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity.
Rhys D.O. Jones , Mike Grondine , Alexandra Borodovsky , Maryann San Martin
British Journal of Pharmacology 178 ( 3) 600 -613
2021
A semi-mechanistic pharmacokinetic-pharmacodynamic (PK-PD) model of savolitinib (AZD6094/HMPL-504), a novel MET inhibitor, to explore extent and duration of target inhibition required for optimal efficacy in the EBC-1 mouse xenograft model
Rhys D Jones , Michael Grondine , Alexandra Borodovsky , Maryann San Martin
Cancer Research 78 ( 13\_Supplement) 4263 -4263
2
2018
Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
Fabrice Andre , Erika Hamilton , Sherene Loi , Peter Schmid
CANCER RESEARCH 81 ( 4)
2021